According to Epizyme's latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of 2022 the company had 166,990,000 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Year | Shares Outstanding | Change |
---|---|---|
2022 | 0.16 B | 60.27% |
2021 | 0.10 B | 2.56% |
2020 | 0.10 B | 6.86% |
2019 | 95.07 M | 20.4% |
2018 | 78.96 M | 31.83% |
2017 | 59.89 M | 3.25% |
2016 | 58.01 M | 39.04% |
2015 | 41.72 M | 21.74% |
2014 | 34.27 M | 20.54% |
2013 | 28.43 M | 26.8% |
2012 | 22.42 M |
Company | Shares Outstanding | differencediff. | Country |
---|---|---|---|
Novartis NVS | 2,062,000,000 | N/A | ๐จ๐ญ Switzerland |
Abbott Laboratories ABT | 1,734,076,358 | N/A | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 2,028,000,000 | N/A | ๐ฌ๐ง UK |
Seagen
SGEN | 188,135,000 | N/A | ๐บ๐ธ USA |